CSF CXCL10, CXCL9, and Neopterin as Candidate Prognostic Biomarkers for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Human T-lymphotropic virus type 1 (HTLV-1) -associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a rare chronic neuroinflammatory disease. Since the disease course of HAM/TSP varies among patients, there is a dire need for biomarkers capable of predicting the rate of disease progression. However, there have been no studies to date that have compared the prognostic values of multiple potential biomarkers for HAM/TSP. METHODOLOGY/PRINCIPAL FINDINGS: Peripheral blood and cerebrospinal fluid (CSF) samples from HAM/TSP patients and HTLV-1-infected control subjects were obtained and tested retrospectively for several potential biomarkers, including chemokines and other cytokines, and nine optimal candidates were selected based on receiver operating characteristic (ROC) analysis. Next, we evaluated the relationship between these candidates and the rate of disease progression in HAM/TSP patients, beginning with a first cohort of 30 patients (Training Set) and proceeding to a second cohort of 23 patients (Test Set). We defined "deteriorating HAM/TSP" as distinctly worsening function (≥3 grades on Osame's Motor Disability Score (OMDS)) over four years and "stable HAM/TSP" as unchanged or only slightly worsened function (1 grade on OMDS) over four years, and we compared the levels of the candidate biomarkers in patients divided into these two groups. The CSF levels of chemokine (C-X-C motif) ligand 10 (CXCL10), CXCL9, and neopterin were well-correlated with disease progression, better even than HTLV-1 proviral load in PBMCs. Importantly, these results were validated using the Test Set. CONCLUSIONS/SIGNIFICANCE: As the CSF levels of CXCL10, CXCL9, and neopterin were the most strongly correlated with rate of disease progression, they represent the most viable candidates for HAM/TSP prognostic biomarkers. The identification of effective prognostic biomarkers could lead to earlier detection of high-risk patients, more patient-specific treatment options, and more productive clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Poiesz, B. J., Ruscetti, F. W., Gazdar, A. F., Bunn, P. A., Minna, J. D., & Gallo, R. C. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.12.7415 · Cited by 5,043 · cited 5×
“In a previous study, cytokines produced by HTLV-1- infected T-cells in HAM/TSP patients were analyzed, and the results showed that IFN-c was elevated and IL-17 reduced [43,44].”
BackgroundInfluentialEpidemiological Aspects and World Distribution of HTLV-1 Infection
Gessain, A., & Cassar, O. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00388 · Cited by 1,428 · cited 2×
“Aside from Japan, endemic areas for this virus and the associated disorders are mostly located in developing countries in the Caribbean, South America, Africa, the Middle East, and Melanesia [7,8], which may explain why these conditions have remained ill-defined and virtually untreatable for so long [9].”
BackgroundNagai, M., Usuku, K., Matsumoto, W., Kodama, D., Takenouchi, N., Moritoyo, T., Hashiguchi, S., Ichinose, M., Bangham, C. R., Izumo, S., et al. (1998) · Journal of Neurovirology · doi:10.3109/13550289809114225 · Cited by 694
Self-citationYamano, Y., Araya, N., Sato, T., Utsunomiya, A., Azakami, K., Hasegawa, D., Izumi, T., Fujita, H., Aratani, S., Yagishita, N., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006517 · Cited by 140
Self-citation
Cited by
HTLV-1-associated myelopathy/tropical spastic paraparesis
Bangham, C. R. M., Araujo, A., Yamano, Y., & Taylor, G. P. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.12 · Cited by 279
Self-citationMogamulizumab (Anti-CCR4) in HTLV-1-Associated Myelopathy
Sato, T., Coler-Reilly, A. L. G., Yagishita, N., Araya, N., Inoue, E., Furuta, R., Watanabe, T., Uchimaru, K., Matsuoka, M., Matsumoto, N., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1704827 · Cited by 113
Self-citationImmunovirological markers in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)
Enose-Akahata, Y., & Jacobson, S. (2019) · Retrovirology · doi:10.1186/s12977-019-0499-5 · Cited by 49
Self-citationEinsiedel, L., Chiong, F., Jersmann, H., & Taylor, G. P. (2021) · Retrovirology · doi:10.1186/s12977-020-00543-z · Cited by 43
Yamauchi, J., Tanabe, K., Sato, T., Nakagawa, M., Matsuura, E., Tsuboi, Y., Tamaki, K., Sakima, H., Ishihara, S., Ohta, Y., et al. (2022) · Viruses · doi:10.3390/v14010136 · Cited by 31
Self-citation
Metadata
- Authors
- Sato, T., Coler-Reilly, A., Utsunomiya, A., Araya, N., Yagishita, N., Ando, H., Yamauchi, J., Inoue, E., Ueno, T., Hasegawa, Y., Nishioka, K., Nakajima, T., Jacobson, S., Izumo, S., & Yamano, Y.
- Venue
- PLoS Neglected Tropical Diseases
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-10-10
- Volume
- 7
- Issue
- 10
- Pages
- e2479
- ISSN
- 1935-2727 (ISSN-L)
- 1935-2735
- OpenAlex
- W2008080012
- Cited by
- 107
- References
- 4
- FWCI
- 2.83
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CSF CXCL10, CXCL9, and Neopterin as Candidate Prognostic Biomarkers for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis. https://app.cochat.ai/papers/10.1371/journal.pntd.0002479
- The paper
- Sato, T., Coler-Reilly, A., Utsunomiya, A., Araya, N., Yagishita, N., Ando, H., Yamauchi, J., Inoue, E., Ueno, T., Hasegawa, Y., Nishioka, K., Nakajima, T., Jacobson, S., Izumo, S., & Yamano, Y. (2013). CSF CXCL10, CXCL9, and Neopterin as Candidate Prognostic Biomarkers for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis. PLoS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0002479
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.